Arbutus Biopharma Corporation
NMS: ABUSLive Quote
📈 ZcoreAI Score
Our AI model analyzes Arbutus Biopharma Corporation's price action across multiple timeframes using regression channels and statistical scoring.
Get ABUS Z-Score →About Arbutus Biopharma Corporation
Healthcare
Biotechnology
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
📊 Fundamental Analysis
Arbutus Biopharma Corporation demonstrates a profit margin of -237.9%, which is below the sector average, suggesting competitive pressure.
The company recently reported -33.2% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -38.5%, which indicates that capital utilization is currently under pressure.
At a current price of $4.15, ABUS currently sits at the 56th percentile of its 52-week range (Range: $2.94 - $5.10).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$811.23M
Trailing P/E
--
Forward P/E
-25.11
Beta (5Y)
0.74
52W High
$5.10
52W Low
$2.94
Avg Volume
2.28M
Day High
Day Low